Therapeutic effects of hypothermia on Lewisite toxicity.
The cytotoxicity of the arsenical vesicant Lewisite was assessed in first passage cultures of proliferating neonatal human skin keratinocytes. Both munitions grade and distilled Lewisite were extremely toxic with LC(50) values in the low ng/ml range, with no significant differences between them. This similarity in toxicity was also mirrored with respect to their toxic effects on hairless guinea pig skin. Two-, 4- and 6-min vapour exposures of these agents resulted in similar and severe skin injury that was obvious by 3-5h post-exposure and almost maximal at 24h. The toxicity of Lewisite in culture was temperature dependent, with a >10-fold reduction in 24h LC(50) values as the incubation temperature was reduced from 37 to 25 degrees C. However, this cooling induced protection was not persistent. In contrast, cooling of Lewisite exposed hairless guinea pig skin at approximately 10 degrees C for as little as 30 min post-exposure resulted in dramatic and permanent protection, with 4h of cooling almost completely eliminating Lewisite induced skin injury. Further, significant protection was also evident even when cooling was delayed for as long as 2h post-Lewisite exposure. In an effort to investigate whether cooling might also increase the window in which chelation therapy against this vesicant agent would be useful, we examined the protective effects of the heavy metal chelator dimercaptosuccinic acid (DMSA). Topical application to Lewisite exposed skin was extremely protective, even when delayed for 2h after Lewisite. Cooling of Lewisite exposed skin for 2h, followed by DMSA topical application resulted in decreased skin injury compared to either treatment in isolation. It appears that the simple and non-invasive application of cooling measures may provide not only significant therapeutic relief to Lewisite exposed skin, but that it may also increase the therapeutic window in which medical countermeasures against this vesicant agent are useful.
Nelson
Peggy
P
Chemical Biological Defence Section, Defence Research and Development Canada-Suffield, Box 4000, Medicine Hat, Alta., Canada T1A 8K6.
Hancock
James R
JR
Sawyer
Thomas W
TW
D000818:Animals; D001152:Arsenicals; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002614:Chelating Agents / Q000494:pharmacology; D002619:Chemical Warfare Agents / Q000633:toxicity*; D006168:Guinea Pigs; D006801:Humans; D007036:Hypothermia, Induced; D015603:Keratinocytes / Q000187:drug effects; D008297:Male; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D004113:Succimer / Q000494:pharmacology
D001152:Arsenicals; D002614:Chelating Agents; D002619:Chemical Warfare Agents; C035965:lewisite; D004113:Succimer